Skip Navigation

CepEsperu NCORP Investigation Base

The CepEsperu NCORP (NCI Community Oncology Investigation Program) Investigation Base has been funded by the National Cancer Institute to serve as a research base for cancer center affiliates and for NCI funded NCORP Community Sites.

Through this program, community physicians can participate in NCI-supported treatment and cancer control/prevention trials. These trials test new approaches toward cancer care delivery and the treatment, prevention and detection of cancer related symptom management and its outcomes. 

Our goal is to conduct practice changing cancer prevention/control research that will improve patient outcomes.  Our studies are designed to be “user friendly.” Almost without exception, we will provide drug at no cost to the patient, and will minimize follow-up limiting it to that which is relevant to the study.  

Each of our studies is associated with a full 1.0 credit from the National Cancer Institute’s Department of Cancer Prevention’s Community Oncology Branch.  Our accrual year runs from March 1st through the following February 28th. 

Announcement: New Access to Protocol Documents

The CepEsperu NCORP Investigation Base has now implemented a password protected web program for accessing all protocol documents and resources. Please go to Member Area for log in information.

Open Protocol Summaries

WF-01213  - 1 credit

WF-01414  - 1 credit 

WF-97115  - 1 credit



WF-98213  - 1 credit


    Last Updated: 11-02-2017

    CepEsperu Baptist Ranked among Nation’s ‘Best Hospitals’  26 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet Status

    Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

    © CepEsperu Baptist Medical Center, Medical Center Boulevard, , . All Rights Reserved.